Critical Analysis of Parkinson’s Disease Models and Cell-Based Therapy
The degeneration of neurons because of genetic mutations and other factors in aging populations causes serious complications in normal brain function, which can result in a variety of progressive dysfunctions. Parkinson’s disease (PD) is one type of these dysfunctions that constitutes approximately 0.3% of the total population and 1% of the total old-age population (over 60years). Because of the severity of this disease, it has drawn attention from medical and scientific communities around the world. The existing treatments, such as L-DOPA administration and/or deep brain surgery (DBS), have been found to further complicate the case of the patient. Therefore, alternate therapies have been investigated. Currently, cell-based therapy is a potential alternative to the previously mentioned treatments because of the promising results obtained from animal experiments and limited clinical trials. The experimental Parkinson’s disease models have significantly increased our knowledge on the progression of this disease and the scope of cell therapy. At the same time, the data from these models also raise some questions concerning the relevance of these models in a clinical setting and the efficacy of the treatment.
KeywordsEmbryonic Stem Cell Dopaminergic Neuron Mitochondrial Protein Complex Fetal Ventral Mesencephalic Tissue Deep Brain Surgery
- Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043–8048PubMedCrossRefGoogle Scholar
- Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551PubMedGoogle Scholar
- Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Tang MW (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 29:1962–1976PubMedCrossRefGoogle Scholar
- Rhee YH, Ko JY, Chang MY, Yi SH, Kim D, Kim CH, Shim JW, Jo AY, Kim BY, Lee L, Lee SH, Suh W, Park CH, Koh HC, Lee YS, Lanza R, Kim KS (2011) Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest 121:2326–2335PubMedCrossRefGoogle Scholar